Cargando…

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes

Myelodysplastic syndromes (MDSs) belong to a group of clonal bone marrow malignancies. In light of the emergence of new molecules, a significant contribution to the understanding of the pathogenesis of the disease is the study of the B-cell CLL/lymphoma 2 (BCL-2) and the programmed cell death recept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuszczak, Bartłomiej, Wróbel, Tomasz, Wicherska-Pawłowska, Katarzyna, Rybka, Justyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003626/ https://www.ncbi.nlm.nih.gov/pubmed/36902139 http://dx.doi.org/10.3390/ijms24054708

Ejemplares similares

Polymorphisms in the Genes Coding for TLRs, NLRs and RLRs Are Associated with Clinical Parameters of Patients with Acute Myeloid Leukemia
por: Wicherska-Pawłowska, Katarzyna, et al.
Publicado: (2022)

Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases
por: Wicherska-Pawłowska, Katarzyna, et al.
Publicado: (2021)

Infection and expression of Toll-like receptors in lymphoid malignancy patients after autologous stem cell transplantation
por: Wicherska-Pawłowska, Katarzyna, et al.
Publicado: (2021)

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
por: Yang, Xingcheng, et al.
Publicado: (2022)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
por: Yang, Hui, et al.
Publicado: (2013)

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2022)

S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes
por: Cheng, Pinyang, et al.
Publicado: (2019)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2021)

The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2022)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes
por: Graf, Johannes R., et al.
Publicado: (2021)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia
por: Meggyes, Matyas, et al.
Publicado: (2019)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2020)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides
por: Grywalska, Ewelina, et al.
Publicado: (2017)

The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface
por: Meggyes, Matyas, et al.
Publicado: (2019)

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
por: Kammerer-Jacquet, Solène-Florence, et al.
Publicado: (2019)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
por: Bardhan, Kankana, et al.
Publicado: (2016)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
por: Qiao, Xin-wei, et al.
Publicado: (2020)

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
por: Scheffel, Thamiris Becker, et al.
Publicado: (2021)

PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review
por: Adamczyk, Michał, et al.
Publicado: (2022)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
por: Schöniger, Sandra, et al.
Publicado: (2022)

Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
por: Király, Zsófia, et al.
Publicado: (2022)

The Impact of Biologic Treatment on PD-1/PD-L1 Pathway Disturbances in Psoriasis
por: Adamczyk, Michał, et al.
Publicado: (2023)

Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killing
por: Ferrari, Valentina, et al.
Publicado: (2022)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
por: Hirsch, Laure, et al.
Publicado: (2018)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

PD-L1 dimerisation induced by biphenyl derivatives mediates anti-breast cancer activity via the non-immune PD-L1–AKT–mTOR/Bcl2 pathway
por: Zhang, Hua, et al.
Publicado: (2023)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
por: Garcia-Diaz, Angel, et al.
Publicado: (2017)

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
por: Robainas, Marianela, et al.
Publicado: (2017)

Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy
por: Shurin, Michael R., et al.
Publicado: (2022)

The immunomodulatory effect of microglia on ECM neuroinflammation via the PD‐1/PD‐L1 pathway
por: Shen, Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a8378t1c5sqjrutl8o96rrr97m